an increased risk of lower urinary tract symptoms (LUTS) relative to daytime workers, and are also at increased risk for shift work sleep disorder (SWSD), a primary circadian rhythm disorder indicated by excessive daytime sleepiness associated with shiftwork. Here we examine the association between SWSD and LUTS in shift workers. METHODS: Men presenting to a single andrology clinic between July 2014 and September 2016 completed questionnaires that assessed work schedule, SWSD risk, and LUTS (International Prostate Symptom Score (IPSS)). The impact of non-standard shift work and SWSD on IPSS score was assessed using ANOVA and linear regression. RESULTS: Of the 2,487 men who completed the question- naires, 766 (30.8%) reported working non-standard shifts in the past month. Of these, 282 (36.8%) were diagnosed with SWSD. Cohort characteristics are described in Table 1. When controlling for age, comorbidities (via the Charlson Comorbidity Index), and testosterone (T) levels, non-standard shift work was not associated with worse LUTS (P¼0.99). However, non-standard shift workers diagnosed with SWSD had IPSS scores 3.1 points higher than non-standard shift workers without SWSD (P<0.0001). CONCLUSIONS: Non-standard shift workers diagnosed with SWSD have worse LUTS than those without SWSD, suggesting that poor sleep habits, rather than shift work itself, contribute to worse LUTS. Modification of work and sleep schedules may reduce the risk for SWSD and subsequent LUTS. Source of Funding: AWP is a K12 scholar supported by a Male Reproductive Health Research (MRHR) Career Development Physician-Scientist Award (Grant # HD073917- 01) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Program. MP13-13 DOES TREATING NOCTURIA LEAD TO BETTER SLEEP? RESULTS FROM REDUCE Stephen Freedland*, Los Angeles, CA; Lauren Howard, Shalini Jha, Durham, NC; Daniel Moreira, Chicago, IL; Gina-Maria Pomann, Durham, NC; Gerald Andriole, King of Prussia, PA; Ramiro Castro-Santamaria, St. Louis, MO; Martin Hopp, Los Angeles, CA; Claus Roehrborn, Dallas, TX INTRODUCTION AND OBJECTIVES: Older men commonly complain of needing to urinate frequently during the night (nocturia) leading to a lack of sleep and not feeling rested in the morning. We assessed, within the context of REDUCE, a randomized controlled trial of dutasteride use, whether treating lower urinary tract symptoms (LUTS) with dutasteride altered either nocturia or sleep complaints. METHODS: REDUCE was a randomized trial comparing dutasteride 0.5mg/day vs. placebo for chemoprevention of prostate cancer. At baseline, 2-years and 4-years, men completed the Interna- tional Prostate Symptom Score (IPSS) survey and the MOSSS-6 questionnaire, a 6-item scale that assesses sleep and is scored 1-100. To test the differences in IPSS (and specifically nocturia) and MOSSS over the study, we used linear mixed models with predictors of treat- ment, visit, and the interaction between treatment and visit. Models were adjusted for baseline age, digital rectal exam findings, PSA, body mass index, race, smoking status, prostate volume, diabetes, and geographical region. Linear contrasts were used to summarize the ef- fect of treatment on each outcome at each study visit. Subanalyses were conducted in men who were symptomatic (IPSS 8) and men with 2 nocturia episodes a night at baseline. RESULTS: There were 6915 patients with complete baseline data. Baseline characteristics were balanced between treatment arms. Dutasteride resulted in significant improvements in IPSS at 2-years (p<0.001) and 4-years (p<0.001) as well as specifically nocturia epi- sodes at 2-years and (p¼0.005) 4-years (p<0.001). In contrast, treat- ment with dutasteride had no effect on overall sleep function nor any specific domain of sleep including feeling rested in the morning or getting enough sleep (p>0.1 at all visits). When analyses were limited to symptomatic men (IPSS 8) or men with 2 nocturia episodes per night, results were unchanged in that dutasteride improved LUTS including nocturia but had no effect on sleep function including feeling rested in the morning or getting enough sleep. CONCLUSIONS: In men who complain of nocturia resulting in not getting enough sleep, treatment of LUTS with dutasteride signifi- cantly improves LUTS but has no effect on sleep including feeling rested in the morning or getting enough sleep. These results suggest in men with nocturia who complain of poor sleep, the poor sleep is not likely to be due to LUTS but rather likely represents a primary sleep problem. Consideration should be given to referring these men to sleep experts to evaluate for sleep problems like sleep apnea or insomnia. Source of Funding: none MP13-14 STUDYING THE EFFECT OF DIABETES MELLITUS TYPE 2 ON PROSTATE RELATED PARAMETERS: A PROSPECTIVE SINGLE INSTITUTIONAL STUDY. Ahmed Elabbady, Mohamed Mohieeldin Hashad*, Ahmed Kotb, Ali Ghanem, Alexandria, Egypt INTRODUCTION AND OBJECTIVES: Diabetes mellitus (DM) is a serious culprit of male health. A positive association exists between clinical markers of BPH and DM. The aim of this work is to examine the effects of type 2 diabetes mellitus (DM) on the variables associated with prostatic growth including serum PSA, serum testosterone and prostate volume and to correlate these variables with the duration of diabetic treatment. METHODS: Our study was conducted over 3 months recruiting 501 men aged 55 years old or more, of which 207 patients had type 2 DM. Exclusion criteria were active urinary tract infection, suspicious rectal examination, urologic cancers, end organ damage and recent urologic manipulations. Serum PSA and serum testosterone were measured. Prostate volume was determined by abdominal ultrasonog- raphy using ellipsoid formula. This study was approved by the ethical committee and informed consents were obtained from participating patients. RESULTS: The mean patient age was 60.21  5.95 years. The mean PSA, Testosterone and prostate volume for diabetic men were 2.3 ng/ ml, 3 ng/ ml and 56 grams respectively. These were 3.5 ng/ ml, 4 ng/ ml and 51 grams respectively for non-diabetics. (p 0.001, p 0.001, p 0.03 respectively). The mean PSA density was 0.049  0.043 ng/ml/ cm3 in diabetics versus 0.080  0.056 ng/ml/cm3 in non-diabetics (p<0.001). As high BMI in diabetic patients was a confounding factor, multiple regression analysis was done (table 1), confirming the true significant correlation of DM with the studied parameters. e158 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017